BD (Becton, Dickinson and Company) , a leading global medical technology company, today announced a $110 million investment to expand its production of prefillable syringes, helping accelerate ...
Dual anti-platelet therapy remains a cornerstone of the treatment for coronary artery disease. When choosing a second anti-platelet, ticagrelor remains a principal agent after the recent PLATO trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback